Triple negative breast cancer: BRCA1/BRCA2 germline mutation status predicts response to polychemotherapy

  • JAMA Oncology

  • JAMA Oncology
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

IMPORTANCE The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 ger...